DOI: https://doi.org/10.22141/2312-413x.8.1.2020.196170

Place of azithromycin in the treatment of community-acquired pneumonia in children

S.A. Kramarov, L.V. Zakordonets

Abstract


Due to the growing resistance of bacteria to antibacterial drugs, the treatment of pneumonia remains topical medical issue. The article provides international recommendations on the use of antibiotics in the treatment of community-acquired pneumonia in children. Numerous experimental and clinical studies have revealed high efficacy of azithromycin even in the presence of resistant strains. This is due to the peculiarities of pharmacokinetics, pharmacodynamics and the versatility of the mechanisms of action of the drug. To date, azithromycin has not lost its position in the treatment of community-acquired pneumonia, especially in the children.


Keywords


pneumonia; treatment; azithromycin; resistance; children

References


Kassebaum N., Kyu H.H., Zoeckler L. et al. Child and Adolescent Health From 1990 to 2015. JAMA Pediatr. 2017. Vol. 171 (6). P. 573.

Rudan I. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008. Vol. 86 (5). P. 408-416.

McAllister D.A., Liu L., Shi T. et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob. Health. 2019. Vol. 7 (1). P. 47-57.

Jain S., Williams D.J., Arnold S.R. et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. N. Engl. J. Med. 2015. Vol. 372 (9). P. 835-845.

Michelow I.C., Olsen K., Lozano J., Rollins N.K. Epidemio­logy and clinical characteristics of community-acquired pneumonia in hospitalized children Pediatrics. 2004. Vol. 113 (4). P. 701-707.

Oumei H., Xuefeng W., Jianping L. et al. Etiology of community-acquired pneumonia in 1500 hospitalized children. J. Med. Virol. 2018. Vol. 90 (3). P. 421-428.

Poole N.M., Shapiro D.J., Kronman M.P., Hersh A.L. Ambulatory Antibiotic Prescribing for Children with Pneumonia After Publication of National Guidelines: A Cross-Sectional Retrospective Study. Infect. Dis. Ther. 2019. Vol. 27.

Guiguére S., Jacks S., Roberts G. Retrospective comparison azithromycin, claritromycin and erythromycin for treatmeant of foals with Rodococcusequi pneumonia. Journal of Veterinary Internal Medicine. 2004. Vol. 18. P. 568-573.

Amsden G.W. Pneumococcal macrolide resistance — myth or reality? J. Antimicrob. Chemother. 1999. Vol. 44 (1). P. 1-6.

Yamasawa H., Oshikawa K., Ohno S., Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. American Journal of Respiratory Cell and Molecular Bio­logy. 2004. Vol. 30 (4). P. 569-575.

Meyer M., Huaux F., Gavilanes X. et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am. J. Respir. Cell. Mol. Biol. 2009. Vol. 41. P. 590-602.

Beigelman A., Mikols C.L., Gunsten S.P. et al. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir. Res. 2010. Vol. 11. P. 90.

Araki N., Yanagihara K., Morinaga Y. et al. Azithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells. Eur. J. Pharmacol. 2010. Vol. 10. P. 209-214.

Imamura Y., Yanagihara K., Mizuta Y. et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosaautoinducer N- (3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. Antimicrob. Agents Chemother. 2004. Vol. 48 (9). P. 3457-61.

Shimizu T., Shimizu S. Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm. 2012. P. 265-714.

Arason A.J., Joelsson J., Valdimarsdottir B. et al. Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia. Respir. Res. 2019. Vol. 20. P. 129.

Gibson P.G., Yang I.A., Upham J.W. et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017. Vol. 12. P. 659-668.

Kim Y.J., Shin K.S., Lee K.H., Kim Y.R. et al. Clinical Characteristics of Macrolide-Resistant Mycoplasma pneumoniae from Children in Jeju. J. Korean Med. Sci. 2017. Vol. 32 (10). P. 1642-1646.

Sallam M., Abbadi J., Natsheh A. et al. Trends in Antimicrobial Drug Resistance of Streptococcus pneumoniae Isolates at Jordan University Hospital (2000–2018). Antibiotics (Basel). 2019. Vol. 8 (2). P. 41.

Zhanel G.G., Wolter K.D., Calciu C. et al. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. J. Antimicrob. Chemother. 2014. Vol. 69 (10). P. 2835-40.

Fukuda Y., Yanagihara K., Higashiyama Y. et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumonia. S. Eur. Respir. J. 2006. Vol. 27 (5). P. 1020-1025.

Domon H., Oda M., Maekawa T. et al. Streptococcus pneumoniae disrupts pulmonary immune defence via elastase release following pneumolysin-dependent neutrophil lysis. Sci Rep. 2016. № 28. P. 38013.

Baddour L.M., Yu V.L., Klugman K.P. et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. International Pneumococcal Study Group. Am. J. Respir. Crit. Care Med. 2004. Vol. 15. Sup. 170. P. 440-4.

Imöhl M., Reinert R.R., Van der Linden M. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. Int. J. Med. Microbiol. 2015. Vol. 7. P. 776-83.

Hoffmann N., Lee B., Hentzer M. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr2/2 mice. Antimicrob. Agents Chemother. 2007. Vol. 51. P. 3677-3687.

Cao B., Zhao C.J., Yin Y.D. et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 2010. Vol. 15. Supрl. 51 (2). P. 189-194.

Zhang Y., Dai J., Jian H., Lin J. Effects of macrolides on airway microbiome and cytokine of children with bronchiolitis: A systematic review and meta-analysis of randomized controlled trials. Microbiol. Immunol. 2019. Vol. 63 (9). P. 343-349.

Kohno S., Tateda K., Kadota J. et al. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia. J. Infect. Chemother. 2014. Vol. 20 (3). P. 199-207.

Laopaiboon M., Panpanich R., Swa Mya K. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst. Rev. 2015. Vol. 3. P. 001954.

Филимонова О.Ю. Распространение и молекулярные механизмы резистентности к макролипидным антибактериальным препаратам микроорганизмов рода Streptococus в Российской Федерации: Автореф. дис… канд. мед. н. М., 2010.

Vaughn V.M., Flanders S.A., Snyder A. et al. Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study. Ann. Intern. Med. 2019. Vol. 6. № 171 (3). P. 153-163.

Зупанец И., Безуглая Н., Либина В. и др. Оценка взаи­мозаменяемости Азимеда: биоэквивалентность доказана! Ліки України. 2013. Т. 1. C. 57-60.

Paediatric Formulary Committee BNF for children 2016–2017. Vol. 12. London: BMJ Group, Pharmaceutical Press and RCPCH Publications, 2016.

Sharland M., Butler K., Cant A. et al. OSH manual of childhood infections. The blue book. Oxford: Oxford University Press, 2016.

World Health Organisation. Revised WHO classification and treatment of childhood pneumonia at health facilities. World Health Organisation. Geneva, Switzerland, 2014.

Harris M., Clark J., Coote N. et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011. Vol. 66. Suppl. 2. P. 1-23.

Le Saux N., Robinson J.L. Canadian Paediatric Society for Infectious Diseases. Uncomplicated pneumonia in healthy Canadian children and youth: practice points for management. Pediatr. Child Health. 2015. Vol. 20. P. 441-450.

Esposito S., Cohen R., Domingo J.D. et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr. Infect. Dis. J. 2012. Vol. 31. P. 78-85.

Bradley J.S., Byington C.L., Shah S.S. et al. The ma­nagement of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 2011. Vol. 53. P. 25-76.

Hansen M.P., Scott A.M., McCullough A. et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst. Rev. 2019 Jan 18. 1: CD011825. doi: 10.1002/14651858.CD011825.pub2.




Copyright (c) 2020 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта